Dr. Alvira Macanovic reports

VENTRIPOINT'S VMS+ PURCHASED BY MEDICAL CENTER - UNIVERSITY OF FREIBURG

Freiburg Hospital has chosen to adopt Ventripoint Diagnostics Ltd.'s VMS+ as its cardiac diagnostic tool.

The University Medical Centre Freiburg in Breisgau, Germany, is notably one of the largest hospitals in Europe and is recognized as the supraregional centre for the treatment of complicated heart disease. It treats approximately 90,000 inpatients and 897,000 outpatients annually.

Dr. Alvira Macanovic, Ventripoint's president and chief executive officer, stated, "This year the Ventripoint team is laser-focused on sales growth and this sale to a leading institution in Europe is indicative of the sales momentum and traction we are seeing in one of our key markets through the co-operative efforts of our direct sales team, channel partners and trial teams."

The VMS+ will be utilized by the department of congenital heart defects and pediatric cardiology which treats over 4,000 children, youth and young adults with congenital and acquired heart diseases each year. With the VMS+, the cardiac medical centre will be able to make its diagnostic and procedural decisions more efficiently and quickly, leading to better outcomes for patients. The VMS+ will serve as an adjunct to speed up decision-making in patient treatment and as an alternative to cardiac MRI (magnetic resonance imaging) when a patient is contraindicated. Most importantly, VMS+ will be used to aid in diagnosis and in continuous monitoring of patients throughout their journey as performing a VMS+ study fits normal scanning workflows. The VMS+ will also be used to assist in the research of terminal heart failure and mechanical cardiovascular replacement and in pediatric drug trials for congenital heart defects.

Sales, installation and support of the VMS+ in Europe are handled by Angiopro GmbH. The co-operation between Ventripoint and Angiopro ensures optimal customer service, so that all VMS+ users can rely on intensive and timely support.

Ventripoint is committed to elevating cardiac care through innovative products like the VMS+ and will continue to work with health care professionals and institutions to develop solutions that improve the patient care journey.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (artificial intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide its future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the United States, Europe and Canada.

We seek Safe Harbor.